131 related articles for article (PubMed ID: 1866714)
1. Influence of thrombolytic agents on human platelet function.
Rao GH; Wilson RF; White CW; White JG
Thromb Res; 1991 May; 62(4):319-34. PubMed ID: 1866714
[TBL] [Abstract][Full Text] [Related]
2. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
[TBL] [Abstract][Full Text] [Related]
3. Qualitative description of factors involved in the retraction and lysis of dilute whole blood clots and in the aggregation and retraction of platelets.
Taylor FB; Müller-Eberhard HJ
J Clin Invest; 1970 Nov; 49(11):2068-85. PubMed ID: 4248913
[TBL] [Abstract][Full Text] [Related]
4. Temporal effects of thrombolytic agents on platelet function in vivo and their modulation by prostaglandins.
Rudd MA; George D; Amarante P; Vaughan DE; Loscalzo J
Circ Res; 1990 Nov; 67(5):1175-81. PubMed ID: 2146037
[TBL] [Abstract][Full Text] [Related]
5. Lytic solution of platelet-rich plasma clots potentiated platelet response to agonists by action on Ca2+ homeostasis.
Liao CL; Zou QJ
Zhongguo Yao Li Xue Bao; 1993 May; 14(3):214-8. PubMed ID: 8237394
[TBL] [Abstract][Full Text] [Related]
6. Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system.
Bizjak N; Bajd F; Vidmar J; Blinc A; Perme MP; Marder VJ; Novokhatny V; Serša I
Thromb Res; 2014 May; 133(5):908-13. PubMed ID: 24613694
[TBL] [Abstract][Full Text] [Related]
7. Inhibitor-resistant tissue-type plasminogen activator: an improved thrombolytic agent in vitro.
Shohet RV; Spitzer S; Madison EL; Bassel-Duby R; Gething MJ; Sambrook JF
Thromb Haemost; 1994 Jan; 71(1):124-8. PubMed ID: 8165630
[TBL] [Abstract][Full Text] [Related]
8. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
Trusen B; Ries M; Zenker M; Rauh M; Beinder E; Keuper H; Harms D
Semin Thromb Hemost; 1998; 24(6):599-604. PubMed ID: 10066156
[TBL] [Abstract][Full Text] [Related]
9. [Effect of thrombolytic agents on platelets and blood coagulation system].
Suehiro A
Rinsho Byori; 1997 Oct; 45(10):951-6. PubMed ID: 9369072
[TBL] [Abstract][Full Text] [Related]
10. Effects of ionic and nonionic contrast media on clot structure, platelet function and thrombolysis mediated by tissue plasminogen activator in plasma clots.
Carr ME; Carr SL; Merten SR
Haemostasis; 1995; 25(4):172-81. PubMed ID: 7557656
[TBL] [Abstract][Full Text] [Related]
11. Effects of streptokinase, urokinase, and recombinant tissue plasminogen activator on platelet aggregability and stability of platelet aggregates.
Terres W; Umnus S; Mathey DG; Bleifeld W
Cardiovasc Res; 1990 Jun; 24(6):471-7. PubMed ID: 2167173
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
Gurewich V; Pannell R
Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
[TBL] [Abstract][Full Text] [Related]
13. Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728.
Mousa SA; Forsythe MS; Diemer M; Bozarth JM; Reilly TM
Coron Artery Dis; 1994 Nov; 5(11):919-27. PubMed ID: 7719524
[TBL] [Abstract][Full Text] [Related]
14. Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation.
Puri RN; Colman RW
Blood Coagul Fibrinolysis; 1993 Jun; 4(3):465-78. PubMed ID: 8329574
[TBL] [Abstract][Full Text] [Related]
15. A bispecific antifibrin-antiplatelet urokinase conjugate (BAAUC) induces enhanced clot lysis and inhibits platelet aggregation.
Ruef J; Nordt TK; Peter K; Runge MS; Kübler W; Bode C
Thromb Haemost; 1999 Jul; 82(1):109-14. PubMed ID: 10456463
[TBL] [Abstract][Full Text] [Related]
16. In vitro effect of plasmin on human platelet function in plasma. Inhibition of aggregation caused by fibrinogenolysis.
Gouin I; Lecompte T; Morel MC; Lebrazi J; Modderman PW; Kaplan C; Samama MM
Circulation; 1992 Mar; 85(3):935-41. PubMed ID: 1531623
[TBL] [Abstract][Full Text] [Related]
17. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
Yao SK; Ober JC; Ferguson JJ; Anderson HV; Maraganore J; Buja LM; Willerson JT
Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
[TBL] [Abstract][Full Text] [Related]
18. Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation.
Bode C; Meinhardt G; Runge MS; Freitag M; Nordt T; Arens M; Newell JB; Kübler W; Haber E
Circulation; 1991 Aug; 84(2):805-13. PubMed ID: 1860223
[TBL] [Abstract][Full Text] [Related]
19. Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates.
Holvoet P; Dewerchin M; Stassen JM; Lijnen HR; Tollenaere T; Gaffney PJ; Collen D
Circulation; 1993 Mar; 87(3):1007-16. PubMed ID: 8443877
[TBL] [Abstract][Full Text] [Related]
20. Systemic lysis protects against the effects of platelet activation during coronary thrombolysis.
Fitzgerald DJ; Hanson M; FitzGerald GA
J Clin Invest; 1991 Nov; 88(5):1589-95. PubMed ID: 1939647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
